Neurocrine Bio. (NBIX) PT Raised to $200 at Oppenheimer, 'increasingly optimistic for NBIX's M4 agonist ahead of Ph2 topline results'
Tweet Send to a Friend
(Updated - March 12, 2024 5:32 PM EDT)
Oppenheimer analyst Jay Olson raised the price target on Neurocrine Bio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jay Olson raised the price target on Neurocrine Bio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
